Gefarnate
Systematic (IUPAC) name | |
---|---|
(2E)-3,7-dimethylocta-2,6-dien-1-yl (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate | |
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Identifiers | |
CAS Number | 51-77-4 |
ATC code | A02BX07 (WHO) |
PubChem | CID 5282182 |
ChemSpider | 4445377 |
UNII | 1ISE2Y6ULA |
KEGG | D01529 |
ChEMBL | CHEMBL2105085 |
Chemical data | |
Formula | C27H44O2 |
Molar mass | 400.637 g/mol |
| |
| |
(what is this?) (verify) |
Gefarnate is a drug used for the treatment of gastric ulcers.[1]
It also has been proposed for use in the treatment of dry eye syndrome.[2][3]
References
- ↑ Ohta Y, Kobayashi T, Imai Y, Inui K, Yoshino J, Nakazawa S (August 2005). "Effect of gefarnate on acute gastric mucosal lesion progression in rats treated with compound 48/80, a mast cell degranulator, in comparison with that of teprenone". Biol. Pharm. Bull. 28 (8): 1424–30. doi:10.1248/bpb.28.1424. PMID 16079487.
- ↑ Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J (April 2008). "Therapeutic targets in dry eye syndrome". Drug News Perspect. 21 (3): 166–76. PMID 18560615.
- ↑ Gipson IK, Hori Y, Argüeso P (April 2004). "Character of ocular surface mucins and their alteration in dry eye disease". Ocul Surf 2 (2): 131–48. doi:10.1016/s1542-0124(12)70149-0. PMID 17216084.
|
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.